Evolus, Inc. (NASDAQ:EOLS – Get Rating) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 1,950,000 shares, a decline of 5.3% from the August 31st total of 2,060,000 shares. Based on an average daily trading volume, of 502,100 shares, the days-to-cover ratio is presently 3.9 days. Approximately 5.3% of the company's shares are short sold.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC started coverage on Evolus in a research report on Thursday, June 23rd. They set a "buy" rating and a $18.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.33.

Evolus Price Performance

Evolus stock opened at $8.05 on Monday. Evolus has a 52 week low of $5.06 and a 52 week high of $14.34. The business has a 50-day simple moving average of $9.88 and a 200 day simple moving average of $11.22. The company has a quick ratio of 2.36, a current ratio of 2.60 and a debt-to-equity ratio of 1.53. The stock has a market cap of $451.56 million, a price-to-earnings ratio of -5.71 and a beta of 2.01.

Insider Transactions at Evolus

In other Evolus news, major shareholder Medytox Inc. sold 26,000 shares of the company's stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $13.28, for a total transaction of $345,280.00. Following the completion of the transaction, the insider now owns 7,437,652 shares of the company's stock, valued at approximately $98,772,018.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Robert Hayman bought 8,909 shares of Evolus stock in a transaction dated Friday, September 9th. The shares were bought at an average cost of $10.35 per share, with a total value of $92,208.15. Following the acquisition, the director now owns 8,909 shares in the company, valued at approximately $92,208.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Medytox Inc. sold 26,000 shares of the firm's stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $13.28, for a total value of $345,280.00. Following the completion of the sale, the insider now directly owns 7,437,652 shares in the company, valued at $98,772,018.56. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 14,967 shares of company stock worth $153,887 and sold 114,300 shares worth $1,253,957. Corporate insiders own 7.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. First Manhattan Co. boosted its stake in shares of Evolus by 22.5% in the 1st quarter. First Manhattan Co. now owns 4,084,938 shares of the company's stock worth $45,833,000 after buying an additional 750,022 shares during the last quarter. Deerfield Management Company L.P. Series C raised its holdings in Evolus by 195.5% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,632,751 shares of the company's stock worth $42,140,000 after purchasing an additional 2,403,517 shares during the period. Stonepine Capital Management LLC raised its holdings in Evolus by 521.0% during the fourth quarter. Stonepine Capital Management LLC now owns 1,863,096 shares of the company's stock valued at $12,129,000 after acquiring an additional 1,563,096 shares during the period. Vanguard Group Inc. raised its holdings in Evolus by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,807,218 shares of the company's stock valued at $20,277,000 after acquiring an additional 69,804 shares during the period. Finally, AIGH Capital Management LLC bought a new stake in Evolus during the first quarter valued at about $10,249,000. Institutional investors own 50.60% of the company's stock.

About Evolus

(Get Rating)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Recommended Stories

• Get a free copy of the StockNews.com research report on Evolus (EOLS)
• Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
• Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
• Magna International is Your Auto and EV One-Stop Shop Stock
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.